Stock Analysis·← Pickers

OKYO

OKYO Pharma Limited

OKYO Pharma Limited (OKYO) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 41.9, with 0/3 trend checks passing.

Price
$1.49
2026-07-16
Trend score
0/3
Downtrend
RSI (14)
41.9
Neutral
Price above MA50Price above MA200MA50 above MA200
Change stock
Search another ticker to view its stock analysis page.
Chart View

OKYO with MA50 and MA200

3.272.832.381.941.4907/3110/2401/2204/1707/15
OKYO2025-07-312026-07-15
PriceMA50MA200
Technical Indicators

Key levels & signals

MA50
$1.61-7.27% vs price
MA200
$1.89-21.30% vs price
RSI (14)
41.9Neutral zone
MACD Signal
MixedMACD near signal line
Macro Support
$1.42–$1.443.4% below price · 3 touches
Support Quality
3 touches0.6× zone volume
Chart Summary
Trend summary for OKYO

OKYO Pharma Limited (OKYO) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $1.49, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 7.3% and below the 200-day moving average by 21.3%.

Momentum and stretch context

OKYO currently has an RSI reading of 41.9, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.

What traders may watch next

For traders reviewing OKYO next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.

Company profile

About OKYO Pharma Limited

OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.

Sector
Healthcare
Industry
Biotechnology
CEO
Robert J. Dempsey
Employees
4
Market cap
$57.2M
Beta
0.04
52-week range
$1.42 – $3.35
Dividend
No
Exchange
NASDAQ
Country
GB
IPO date
17 May 2022
ISIN
GG00BMFG5F62
CUSIP
679345108
Company profile data from Financial Modeling Prep. OKYO listed on NASDAQ.
Share dilution

OKYO shares outstanding over time

Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.

Sept 2012Sept 2025
Shares outstanding (latest)
37.4M
Since Sept 2012
+773.7%
Trend
More shares outstanding
Historical shares-outstanding data from Financial Modeling Prep. OKYO27 data points from Sept 2012 to Sept 2025.
Learn More

Learn the indicators behind this page

Explore More

More stock opportunities

FAQ

Common questions about OKYO

Is this page a buy or sell recommendation?

No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.

Why can a stock look bullish and overbought at the same time?

Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.

What should I do next after reading this page?

Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.